KR20220023421A - A method for preparing beriberi-treating medicine and the beriberi-treating medicine prepared therefrom - Google Patents
A method for preparing beriberi-treating medicine and the beriberi-treating medicine prepared therefrom Download PDFInfo
- Publication number
- KR20220023421A KR20220023421A KR1020200105123A KR20200105123A KR20220023421A KR 20220023421 A KR20220023421 A KR 20220023421A KR 1020200105123 A KR1020200105123 A KR 1020200105123A KR 20200105123 A KR20200105123 A KR 20200105123A KR 20220023421 A KR20220023421 A KR 20220023421A
- Authority
- KR
- South Korea
- Prior art keywords
- beriberi
- therapeutic agent
- treatment
- medical
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 의약품의 조제 방법에 관한 것으로, 특히 각기병 치료제의 조제 방법에 관한 것이고, 또한이 방법으로 제조된 각기병 치료제에 관한 것이다.The present invention relates to a method for preparing a pharmaceutical product, and more particularly to a method for preparing a therapeutic agent for beriberi, and also to a therapeutic agent for beriberi produced by the method.
각기병(Beriberi)은 일반적인 피부 질환으로, 일반적으로 발 부분의 피부에 붉은 반점, 가려움증 및 피부 벗겨짐을 유발한다. 각기병은 심각한 질병은 아니지만 밤낮으로 사람을 괴롭히고 정상적인 일과 생활에 영향을 미친다. 그리고 심한 각기병 환자는 피부 궤양과 고름 분비물로 고통 받고 심지어 걸을 수 없다. 현재 각기병 치료제는 많이 있지만 효과가 느리거나 효과가 나쁘거나 재발률이 높아 환자의 요구에 부응할 수 없다.Beriberi is a common skin disease that causes red spots, itching, and peeling of the skin, usually on the feet area. Although beriberi is not a serious disease, it afflicts people day and night and affects normal work and life. And people with severe beriberi suffer from skin ulcers and pus discharge and cannot even walk. Currently, there are many treatments for beriberi, but the effect is slow, the effect is poor, or the recurrence rate is high, so it cannot meet the needs of patients.
본 발명의 목적은 각기병 치료제의 제조 방법 및 그 방법으로 제조된 각기병 치료제를 제공하는 것이다. 본 발명의 제조 방법으로 제조된 각기병 치료제는 효과가 빠르고 효과가 좋고 재발률이 낮으며 현재의 각기병 치료제의 단점을 극복한다.It is an object of the present invention to provide a method for manufacturing a therapeutic agent for beriberi and a therapeutic agent for beriberi produced by the method. The therapeutic agent for beriberi produced by the manufacturing method of the present invention has a fast and effective effect and a low recurrence rate, and overcomes the disadvantages of the current therapeutic agent for beriberi.
본 발명에 따른 각기병 치료제의 제조 방법은 다음과 같은 단계를 포함한다.The method for preparing a therapeutic agent for beriberi according to the present invention includes the following steps.
1. 원료 준비:1. Raw material preparation:
적작약(Radix Paeoniae Rubra) 분말 60-80mg, 0.2-0.3 wt.% 벤조산 100-120mg, 미코나졸 질산염(miconazole nitrate) 8-10mg, 5-10 wt.% 살리실산 60-80mg, 클로베타솔 프로피오네이트(clobetasol propionate) 1-3mg, 의료용 바셀린 5-7mg 및 75 wt.% 의료용 에탄올 1ml.Radix Paeoniae Rubra powder 60-80mg, 0.2-0.3 wt.% benzoic acid 100-120mg, miconazole nitrate 8-10mg, 5-10 wt.% salicylic acid 60-80mg, clobetasol propionate (clobetasol propionate) 1-3 mg, medical grade petrolatum 5-7 mg and 75 wt.% medical grade ethanol 1 ml.
바람직하게는 원료 및 그 함량은 다음과 같다: 적작약 분말 70-80mg, 0.2-0.3wt.% 벤조산 100-115mg, 미코나졸 질산염 8-9mg, 5-10 wt.% 살리실산 60 -75mg, 클로베타솔 프로피오네이트 2-3mg, 의료용 바셀린 6-7mg 및 75 wt.% 의료용 에탄올 1ml;Preferably, the raw material and its content are as follows: red peony powder 70-80mg, 0.2-0.3wt.% benzoic acid 100-115mg, miconazole nitrate 8-9mg, 5-10 wt.% salicylic acid 60-75mg, clobetasol 2-3 mg propionate, 6-7 mg medical grade petrolatum and 1 ml 75 wt.% medical grade ethanol;
2. 필요한 양의 적작약 분말, 0.2-0.3 wt.% 벤조산, 5-10 wt.% 살리실산, 미코나졸 질산염, 클로베타솔 프로피오네이트 및 의료용 바셀린을 필요한 양의 75wt.% 의료용 에탄올에 순차적으로 첨가하고 균일하게 교반하여 각기병 치료제를 수득한다;2. Sequentially add the required amount of red peony powder, 0.2-0.3 wt.% benzoic acid, 5-10 wt.% salicylic acid, miconazole nitrate, clobetasol propionate and medical grade petrolatum to the required amount of 75 wt.% medical grade ethanol and uniformly stirred to obtain a therapeutic agent for beriberi;
3. 수득한 각기병 치료제를 각 병에 25-50mL씩 병에 나누어 넣고 밀봉한다.3. Divide the obtained beriberi treatment by 25-50mL into each bottle and seal.
본 발명의 각기병 치료제의 사용 방법 (외용)은: 각기병 치료제를 환부에 1 일 2 회 도포하는 단계; 및 증상이 사라진 후 1 ~ 2 주 더 각기병 치료제를 계속 도포하는 단계를 포함하며, 각기병 치료제 도포 중에는 술 및 매운 음식의 섭취가 금지된다. 이 치료제는 알코올과 이 치료제에 알레르기가 있는 사람들에게 금지된다. 이 치료제는 알레르기가 있는 사람과 수유중인 여성에게 주의해서 사용해야 한다.The method of using the therapeutic agent for beriberi of the present invention (for external use) comprises the steps of: applying the therapeutic agent for beriberi to the affected area twice a day; and continuing to apply the beriberi treatment agent for 1 to 2 weeks after the symptoms disappear, while alcohol and spicy food are prohibited while the beriberi agent is applied. This treatment is contraindicated in people who are allergic to alcohol and to this treatment. This treatment should be used with caution in people with allergies and in lactating women.
본 발명의 각기병 치료제는 중국 한약 원료와 양약 원료를 함께 사용하여 상승효과를 충분히 발휘한다. 중국 한약 원료와 양약 원료와 양약 원료의 합리적인 비율은 빠른 효과, 좋은 효과 및 낮은 재발률의 특성을 부여한다. 본 발명의 각기병 치료제를 적용한 후, 환자는 통증 없이 약간의 불편함을 느낄 것이다. 각기병 치료제는 도포 후 빠르게 증발하는 에탄올을 함유하고 있으며 소량의 바셀린을 함유하고 있어 도포 후에도 피부가 건조하지 않는다. 그리고 각기병 치료제는 사용하기 쉽고 적용 후 환자가 편안함을 느낄 것이다. 본 발명의 각기병 치료제는 3000명 이상의 환자를 치료하는데 사용되었으며 총 유효율은 9%, 치료율은 93%, 무효과율은 2%이다. 일반적으로 각기병 치료제를 도포한 후 30분 후에 가려움증이 완화되기 시작한다. 1-3일 후에 관련 증상이 사라지거나 (경미한 환자의 경우) 현저하게 완화된다 (중증 환자의 경우). 증상이 사라진 후 치료제를 1-2 주 동안 계속 적용하면 치료 효과를 얻을 수 있다. 재발률이 낮다.The therapeutic agent for beriberi of the present invention fully exhibits a synergistic effect by using both Chinese herbal and western medicine raw materials. The reasonable ratio of Chinese herbal medicine raw materials and western medicine raw materials to western medicine raw materials gives the characteristics of fast effect, good effect and low recurrence rate. After applying the treatment for beriberi of the present invention, the patient will experience some discomfort without pain. The treatment for beriberi contains ethanol that evaporates quickly after application and contains a small amount of petrolatum, so the skin does not dry out after application. And the treatment for beriberi is easy to use and the patient will feel comfortable after application. The therapeutic agent for beriberi of the present invention has been used to treat more than 3000 patients, and the total effective rate is 9%, the cure rate is 93%, and the ineffective rate is 2%. In general, itching begins to subside 30 minutes after applying the beriberi drug. Relevant symptoms disappear (in mild patients) or significantly relieve (in severe patients) after 1-3 days. After the symptoms disappear, the treatment may be effective if the treatment is continued for 1-2 weeks. The recurrence rate is low.
본 발명의 각기병 치료제는 조제가 간단하고, 비용이 저렴하고 효과가 좋으며, 적은 비용으로 대부분의 환자의 요구를 충족시킬 수 있고, 단시간에 통증을 완화할 수 있으며, 재발이 적다. 환자가 정상적인 일과 생활로 돌아갈 수 있도록 도와준다.The therapeutic agent for beriberi of the present invention is simple to prepare, inexpensive and effective, can satisfy the needs of most patients at low cost, can relieve pain in a short time, and has little recurrence. Help patients return to normal work and life.
본 발명에 필요한 원료 및 장비는 상업적으로 구할 수 있다.Raw materials and equipment necessary for the present invention are commercially available.
예 1Example 1
상술한 각기병 치료제의 제조 방법에 따라 각기병 치료제를 제조하며, 상기 단계 1)에서 원료 및 함량은 다음과 같다: 적작약(Radix Paeoniae Rubra) 분말 60000mg, 벤조산 100000mg, 살리실산 80000mg, 미코나졸 질산염 10000mg, 클로베타솔 프로피오네이트 1000mg, 의료용 바셀린 5000mg 및 의료용 에탄올 1000ml; 그리고 단계 3)에서, 각 병에 25 mL로 각기병 치료제를 분할 충전한다.A treatment for beriberi is prepared according to the above-described method for the treatment of beriberi, and the raw materials and contents in step 1) are as follows: Red peony (Radix Paeoniae Rubra) powder 60000 mg, benzoic acid 100000 mg, salicylic acid 80000 mg, miconazole nitrate 10000 mg, clobeta sol propionate 1000mg, medical grade petrolatum 5000mg and medical grade ethanol 1000ml; And in step 3), each bottle is filled with 25 mL of beriberi treatment in divided portions.
예 2Example 2
상술한 각기병 치료제의 제조 방법에 따라 각기병 치료제를 제조하며, 상기 단계 1)에서 원료 및 함량은 다음과 같다: 적작약(Radix Paeoniae Rubra) 분말 80000mg, 벤조산 120000mg, 살리실산 60000mg, 미코나졸 질산염 8000mg, 클로베타솔 프로피오네이트 3000mg, 의료용 바셀린 7000mg 및 의료용 에탄올 1000ml; 그리고 단계 3)에서, 각 병에 50 mL로 각기병 치료제를 분할 충전한다.A treatment for beriberi is prepared according to the above-described method for preparing a treatment for beriberi, and the raw materials and contents in step 1) are as follows: Red peony (Radix Paeoniae Rubra) powder 80000 mg, benzoic acid 120000 mg, salicylic acid 60000 mg, miconazole nitrate 8000 mg, clobeta sol propionate 3000mg, medical grade petrolatum 7000mg and medical grade ethanol 1000ml; And in step 3), fill each bottle with 50 mL of beriberi treatment in divided portions.
예제 3Example 3
상술한 각기병 치료제의 제조 방법에 따라 각기병 치료제를 제조하며, 상기 단계 1)에서 원료 및 함량은 다음과 같다: 적작약(Radix Paeoniae Rubra) 분말 70000mg, 벤조산 115000mg, 살리실산 75000mg, 미코나졸 질산염 9000mg, 클로베타솔 프로피오네이트 2000mg, 의료용 바셀린 6000mg 및 의료용 에탄올 1000ml; 그리고 단계 3)에서, 각 병에 25 mL로 각기병 치료제를 분할 충전한다..A treatment for beriberi is prepared according to the above-described method for preparing a treatment for beriberi, and the raw materials and contents in step 1) are as follows: Red peony (Radix Paeoniae Rubra) powder 70000 mg, benzoic acid 115000 mg, salicylic acid 75000 mg, miconazole nitrate 9000 mg, clobeta sol propionate 2000mg, medical grade petrolatum 6000mg and medical grade ethanol 1000ml; And in step 3), fill each bottle with 25 mL of beriberi treatment in divided portions.
임상 관찰 요약Summary of clinical observations
I. 각기병의 진단 기준 : 발 부분은 붉은 반점, 가려움증, 피부 벗겨짐, 심지어 피부 궤양과 고름 분비물로 심하게 고통받는다.I. Criteria for the diagnosis of beriberi: The foot area suffers severely from red spots, itching, peeling of the skin, and even skin ulcers and pus discharge.
II. 본 발명의 각기병 치료제의 사용 방법 (외용)은 각기병 치료제를 환부에 1 일 2 회 도포하는 단계; 및 증상이 사라진 후 1 ~ 2 주 더 각기병 치료제를 계속 도포하는 단계를 포함하며, 각기병 치료제 도포 중에는 술 및 매운 음식의 섭취가 금지된다. 이 치료제는 알코올과 이 치료제에 알레르기가 있는 사람들에게 금지된다. 이 치료제는 알레르기가 있는 사람과 수유중인 여성에게 주의해서 사용해야 한다.II. The method of using the therapeutic agent for beriberi of the present invention (for external use) comprises the steps of applying the therapeutic agent for beriberi to the affected area twice a day; and continuing to apply the beriberi treatment agent for 1 to 2 weeks after the symptoms disappear, while alcohol and spicy food are prohibited while the beriberi agent is applied. This treatment is contraindicated in people who are allergic to alcohol and to this treatment. This treatment should be used with caution in people with allergies and in lactating women.
III. 치료 효과의 평가 기준:III. Criteria for evaluation of therapeutic effect:
1. 효과있음: 증상이 완전히 사라지고 피부가 정상으로 회복되며 8 ~ 12개월 후 재발한다.1. Effective: Symptoms disappear completely, skin returns to normal, and recurrence occurs after 8 to 12 months.
2. 치료: 증상이 완전히 사라지고 피부는 재발없이 정상으로 회복된다.2. Treatment: The symptoms disappear completely and the skin returns to normal without recurrence.
3. 효과없음(무효과 : 가려움증이 완화되고 증상이 약간 바뀐다.3. No effect (no effect: itching is relieved and symptoms are slightly changed.
IV. 치료 효과: 총 300명의 환자가 임상 적으로 관찰되었으며, 60명의 환자가 6개월 이하 각기병을 앓았으며 140명의 환자가 1 ~ 5년 동안 각기병을 앓았으며 100명의 환자가 10년 미만의 각기병을 앓고 있었다. 치료 결과 294명의 환자가 효과적으로 치료를 받았다; 279명의 환자가 치료되었고 15명의 환자는 치료 후 재발했다. 반면 6명의 환자는 치료효과가 없었다. 결과적으로 총 유효율 98%, 치료율 9%, 재발율 5%, 무효과율 2%이다.IV. Treatment effect: A total of 300 patients were clinically observed, 60 patients had beriberi for less than 6 months, 140 patients had beriberi for 1 to 5 years, and 100 patients had beriberi for less than 10 years. . Treatment Results 294 patients were treated effectively; 279 patients were cured and 15 patients relapsed after treatment. On the other hand, 6 patients had no treatment effect. As a result, the total efficacy rate is 98%, the cure rate is 9%, the recurrence rate is 5%, and the invalidity rate is 2%.
전형적인 사례typical case
1. 저우씨(여, 23세)는 10년 이상 각기증을 앓고 있었는데, 그동안 때때로 기분이 나아지고 때때로 참을 수 없을 정도로 고통스러웠고, 10가지 이상의 각기병 치료제를 사용했지만 그 효과는 안 좋다. 그녀의 두 발은 통증과 가려움증을 동반한 농포성 젖은 각기증으로 고통받았다. 본 발명의 각기병 치료제로 치료한 후 치료받은 당일 가려움증이 사라졌다. 관련 증상은 3일 후에 현저히 완화되었다. 그리고 증상은 1주 후에 사라졌다. 그 후 약을 1주일 더 계속 도포했고, 각기병은 지금까지 재발하지 않았다.1. Ms. Zhou (female, 23 years old) has suffered from beriberi for more than 10 years. During that time, she felt better and sometimes unbearably painful. She used more than 10 different beriberi treatments, but the effect was not good. Her two feet suffered from pustular wet beriberi accompanied by pain and itching. After treatment with the therapeutic agent for beriberi of the present invention, itching disappeared on the day of treatment. Relevant symptoms were significantly relieved after 3 days. And the symptoms disappeared after 1 week. After that, the drug continued to be applied for another week, and beriberi has not recurred so far.
2. 리씨 (여, 28세)는 4년 동안 각기증을 앓고 있었으며 그녀의 두 발은 견딜 수 없는 가려움증과 통증을 동반한 표재성미란형성(anabrotic) 습성 각기증으로 고통받았다. 본 발명의 각기병 치료제로 치료 후, 가려움증과 통증은 1일 후 사라졌다. 관련 증상은 3일 후에 완화되었다. 그리고 증상은 1주 후에 사라졌다. 그 후 약을 1주일 더 계속 도포했고, 각기는 지금까지 재발하지 않았다.2. Ms. Li (female, 28 years old) had suffered from beriberi for 4 years and suffered from superficial anabrotic wet beriberi with unbearable itching and pain in her feet. After treatment with the therapeutic agent for beriberi of the present invention, itching and pain disappeared after 1 day. Relevant symptoms were relieved after 3 days. And the symptoms disappeared after 1 week. After that, the drug continued to be applied for another week, and beriberi has not relapsed so far.
3. 장씨 (남, 30세)는 각기병을 앓아 약국에서 7 ~ 8종의 각기병 치료제를 구입했는데 효과가 좋지 않아 각기증이 반복적으로 재발하고 그의 두 발은 황수 분비물, 피부 벗겨짐, 가려움증 및 통증을 동반한 농포성 병변이었다. 본 발명의 각기병 치료제로 치료한 후, 2일째에 가려움증이 사라졌다. 관련 증상은 3일 후에 현저히 완화되었다. 그리고 증상은 1주 후에 사라졌다. 그 후 약을 1주일 더 계속 도포했고, 각기는 지금까지 재발하지 않았다.3. Mr. Jang (male, 30 years old) suffered from beriberi and bought 7 to 8 types of beriberi treatment at the pharmacy, but the effect was not good, so beriberi recurred repeatedly. It was accompanied by a pustular lesion. After treatment with the therapeutic agent for beriberi of the present invention, the itching disappeared on the second day. Relevant symptoms were significantly relieved after 3 days. And the symptoms disappeared after 1 week. After that, the drug continued to be applied for another week, and beriberi has not relapsed so far.
4. 송씨 (여, 48세)는 10년 넘게 각기병으로 고통 받았으며 많은 약을 사용했지만 완치된 적이 없었다. 경제적 어려움으로 그녀는 증상이 심할 때만 약을 사용하고 증상이 경미할 때 약을 사용하지 않았다. 발바닥의 오래된 피부는 매우 두껍고 노출된 신선한 피부는 물집, 통증 및 가려움증을 동반한 붉은 반점을 겪었다. 본 발명의 각기병 치료제로 치료 후, 오래된 피부는 점차적으로 벗겨지고, 가려움증은 사라지고 1주일 후에 신선한 피부가 자랐다. 발바닥 전체의 오래된 피부는 완전히 벗겨졌고 각기는 1주일 후에 치료되었다. 그 후 10일 동안 계속해서 약을 바르고 각기병은 4년 이상 지금까지 재발하지 않았다.4. Mr. Song (female, 48 years old) has suffered from beriberi for over 10 years and has used many medications, but has never been cured. Due to financial difficulties, she only used the drug when the symptoms were severe and did not use it when the symptoms were mild. The old skin on the soles of the feet was very thick and the fresh skin exposed suffered red spots accompanied by blisters, pain and itching. After treatment with the therapeutic agent for beriberi of the present invention, the old skin gradually peeled off, the itching disappeared, and fresh skin grew after one week. The old skin all over the soles of the feet was completely peeled off and each healed after a week. After that, the drug continued to be applied for 10 days, and beriberi did not recur for more than 4 years.
5. 자오씨 (여, 26세)는 각기병을 앓고 있어 중증으로 치료를 위해 외용제와 수액제를 사용했지만 효과가 좋지 않았다. 그녀의 두 발은 부어 오르고 표재성미란형성이었고 농포, 황수 분비물, 견딜 수 없는 통증과 가려움증을 동반했다. 항생제의 경구 투여와 함께 본 발명의 각기병 치료제로 치료한 후, 5일 후에 발이 부어 오르지 않고 농포가 사라지고 신선한 피부가 자랐다. 그 후 항생제를 중단하고 본 발명의 각기병 치료제를 2주 더 계속 도포한 후 각기는 완치되었고 2년 이상 지금까지 재발하지 않았다.5. Mr. Zhao (female, 26 years old) suffers from beriberi and used external preparations and infusions for treatment, but the effect was not good. Her feet were swollen and superficial erosions, accompanied by pustules, yew discharge, intolerable pain and itching. After treatment with the therapeutic agent for beriberi of the present invention along with oral administration of antibiotics, the feet did not swell after 5 days, the pustules disappeared, and fresh skin grew. After that, the antibiotic was stopped and the beriberi treatment agent of the present invention was continuously applied for 2 more weeks, and the beriberi was completely cured, and there has been no recurrence for more than 2 years.
Claims (4)
적작약(Radix Paeoniae Rubra) 분말 60-80mg, 0.2-0.3 wt.% 벤조산 100-120mg, 미코나졸 질산염(miconazole nitrate) 8-10mg, 5-10 wt.% 살리실산 60-80mg, 클로베타솔 프로피오네이트(clobetasol propionate) 1-3mg, 의료용 바셀린 5-7mg 및 75 wt.% 의료용 에탄올 1ml를 포함하는 원료 물질을 준비하고;
상기 필요한 양의 적작약 분말, 벤조산, 살리실산, 미코나졸 질산염, 클로베타솔 프로피오네이트 및 의료용 바셀린을 상기 필요한 양의 의료용 에탄올에 순차적으로 첨가하고 균일하게 교반하여 각기병 치료제를 수득하고;
수득한 각기병 치료제를 각 병에 25-50mL씩 병에 나누어 넣고 밀봉하는 함을 포함하는,
각기병 치료제 제조 방법.A method for the preparation of a treatment for beriberi, the method comprising:
Radix Paeoniae Rubra powder 60-80mg, 0.2-0.3 wt.% benzoic acid 100-120mg, miconazole nitrate 8-10mg, 5-10 wt.% salicylic acid 60-80mg, clobetasol propionate (clobetasol propionate) 1-3mg, medical grade petrolatum 5-7mg and 75 wt.% medical grade ethanol 1ml preparing a raw material;
The required amounts of red peony powder, benzoic acid, salicylic acid, miconazole nitrate, clobetasol propionate and medical petrolatum are sequentially added to the required amount of medical ethanol and uniformly stirred to obtain a therapeutic agent for beriberi;
Including dividing the obtained beriberi treatment agent into bottles by 25-50mL in each bottle and sealing,
A method of manufacturing a treatment for beriberi.
상기 원료 물질은 적작약 분말 70-80mg, 0.2-0.3wt.% 벤조산 100-115mg, 미코나졸 질산염 8-9mg, 5-10 wt.% 살리실산 60 -75mg, 클로베타솔 프로피오네이트 2-3mg, 의료용 바셀린 6-7mg 및 75 wt.% 의료용 에탄올 1ml을 포함하는,
각기병 치료제 제조 방법.According to claim 1,
The raw material is red peony powder 70-80mg, 0.2-0.3wt.% benzoic acid 100-115mg, miconazole nitrate 8-9mg, 5-10 wt.% salicylic acid 60-75mg, clobetasol propionate 2-3mg, medical grade 6-7 mg of petrolatum and 1 ml of 75 wt.% medical grade ethanol;
A method of manufacturing a treatment for beriberi.
상기 원료 물질은 적작약(Radix Paeoniae Rubra) 분말 70000mg, 0.2-0.3wt.% 벤조산 115000mg, 미코나졸 질산염 9000mg, 5-10wt.% 살리실산 75000mg, 클로베타솔 프로피오네이트 2000mg, 의료용 바셀린 6000mg 및 75wt.% 의료용 에탄올 1000ml을 포함하는,
각기병 치료제 제조 방법.3. The method of claim 2,
The raw material is red peony (Radix Paeoniae Rubra) powder 70000mg, 0.2-0.3wt.% benzoic acid 115000mg, miconazole nitrate 9000mg, 5-10wt.% salicylic acid 75000mg, clobetasol propionate 2000mg, medical petrolatum 6000mg and 75wt.% containing 1000 ml of medical ethanol,
A method of manufacturing a treatment for beriberi.
적작약(Radix Paeoniae Rubra) 분말 60-80mg, 0.2-0.3wt.% 벤조산 100-120mg, 미코나졸 질산염(miconazole nitrate) 8-10mg, 5-10wt.% 살리실산 60-80mg, 클로베타솔 프로피오네이트(clobetasol propionate) 1-3mg, 의료용 바셀린 5-7mg 및 75wt.% 의료용 에탄올 1ml을 포함하는,
각기병 치료제.
A therapeutic agent for beriberi prepared by the method of any one of claims 1 to 3, wherein the therapeutic agent for beriberi comprises:
Red peony (Radix Paeoniae Rubra) powder 60-80mg, 0.2-0.3wt.% benzoic acid 100-120mg, miconazole nitrate 8-10mg, 5-10wt.% salicylic acid 60-80mg, clobetasol propionate ( clobetasol propionate) 1-3mg, medical grade petrolatum 5-7mg and 75wt.% medical grade ethanol 1ml,
beriberi treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200105123A KR20220023421A (en) | 2020-08-21 | 2020-08-21 | A method for preparing beriberi-treating medicine and the beriberi-treating medicine prepared therefrom |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200105123A KR20220023421A (en) | 2020-08-21 | 2020-08-21 | A method for preparing beriberi-treating medicine and the beriberi-treating medicine prepared therefrom |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220023421A true KR20220023421A (en) | 2022-03-02 |
Family
ID=80815455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200105123A KR20220023421A (en) | 2020-08-21 | 2020-08-21 | A method for preparing beriberi-treating medicine and the beriberi-treating medicine prepared therefrom |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20220023421A (en) |
-
2020
- 2020-08-21 KR KR1020200105123A patent/KR20220023421A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108853312B (en) | Polycinnamic alcohol external gel and preparation method thereof | |
| US5583120A (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
| AU782515B2 (en) | Pharmaceutical and cosmetic carrier or composition for topical application | |
| JP6495183B2 (en) | Compositions and methods for treating surface wounds | |
| KR20110074513A (en) | Topical treatment of skin infection | |
| Litt | Steroid-induced rosacea. | |
| JP2015530380A (en) | Composition for treating psoriasis | |
| WO1994015623A9 (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
| JPH08505388A (en) | Hyaluronic acid-urea pharmaceutical composition and use thereof | |
| RIFKIN et al. | Lithium-induced folliculitis | |
| US3072527A (en) | Use of tolbutamide in the treatment of acne | |
| KR20220000203A (en) | A method for preparing tinea pedis-treating medicine and the tinea pedis-treating medicine prpared therefrom | |
| KR20220023421A (en) | A method for preparing beriberi-treating medicine and the beriberi-treating medicine prepared therefrom | |
| Bitar et al. | A double-blind randomised study of metronidazole (Flagyl®) 1% cream in the treatment of acne rosacea: a placebo-controlled study | |
| US3019165A (en) | Sunburn preventive and burn remedy | |
| WO2012059874A1 (en) | A mouthwash composition for managing oral mucositis, process and methods thereof | |
| US5716646A (en) | Methods and compositions for treating arthritis | |
| KR20220029113A (en) | A method for preparing beriberi-treating medicine and the beriberi-treating medicine prepared therefrom | |
| US20180325973A1 (en) | Skin care composition | |
| KR20010034150A (en) | Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate | |
| KR20210156391A (en) | A method for preparing beriberi-treating medicine and the beriberi-treating medicine prepared therefrom | |
| Günther | Topical administration of vitamin A acid (retinoic acid) in palmar keratoses: callosities, hyperkeratotic eczema, hypertrophic lichen planus, pityriasis rubra pilaris | |
| CN101422430B (en) | Ketoconazole m-thymol liquor for treating skin tinea | |
| Singhal et al. | Topical clobetasol propionate 0.025%: a therapeutic dermatologic asset | |
| DE102020121939A1 (en) | METHOD OF PREPARING BERIBERI TREATMENT MEDICINE AND THE PREPARED BERIBERI TREATMENT MEDICINE |